Navigation Links
ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research

hwestern Medical School, will make on oral presentation on April 1 titled "ACP-104 Novel Atypical Antipsychotic with Potential Cognitive Effects." During the presentation, Dr. Tamminga will review the unique preclinical properties of ACP-104 as well as top-line clinical results from the single ascending-dose and multiple ascending-dose studies with ACP-104, which were announced in July 2006. Additionally, data from the single ascending-dose study will be presented in a poster titled "ACP-104 Safety and Pharmacokinetics in Psychosis."

ACP-104: Demonstrates Pro-Cognitive Actions in Experimental Models

In a poster presentation titled "N-Desmethylclozapine Demonstrates Pro-Cognitive Actions in Experimental Models," ACADIA researchers describe preclinical data that indicate ACP-104, in addition to being active in models predictive of antipsychotic activity, has a superior profile in animal models of cognitive function. ACP-104 showed an improved performance in the Radial Arm Maze and no adverse effect in the Novel Object Recognition assay. In contrast, clozapine impaired performance in both these assays. The pro-cognitive effects of ACP-104 were shown to be dependent upon M1 muscarinic activity. These findings suggest that ACP-104 will have a superior clinical profile with activity against all symptom domains (positive, negative, and cognitive) in schizophrenia.

ACP-104: Unique Receptor Profile for Treating Psychosis

In a poster presentation titled "Comparison of the In Vitro Pharmacology of N-Desmethylclozapine (ACP-104) with other Atypical Antipsychotic Agents," ACADIA researchers describe experiments that used cell based assays to characterize the functional interaction of ACP-104 and other antipsychotic drugs with a number of receptors implicated in the efficacy or adverse effects of antipsychotic drugs. The results demonstrated that ACP-104 has a receptor profile that is distinct from and potentially advantageous to clozapine and other at
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
3. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
4. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
5. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
10. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
11. New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down methamphetamine offenders and make arrests. ... Missouri blocked the sale ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
(Date:8/21/2014)... Aspen Advisors, a U.S.-based healthcare consulting firm, announced today that ... Best Places to Work in Healthcare for 2014. ... creating workplaces that enable employees to perform at their optimum ... an employee engagement and satisfaction survey. This is the ... a “Best Places to Work in Healthcare”. , "We are ...
(Date:8/21/2014)... Absence seizures are believed to be elicited by ... of the brain that regulate influxes of calcium. ... generate burst firing, leading the neurons to enter ... the relationship between burst firing and absence seizures, ... seizures in mice using gene targeting techniques to ...
(Date:8/21/2014)... According to researchers at the University of Montreal, the ... important role as we train our bodies, movements and, ... sleep. While researchers knew that sleep helped us the ... known why. "The subcortical regions are important in information ... When consolidation level is measured after a period of ...
(Date:8/21/2014)... August 21, 2014 Bedros Keuilian’s Annual Fitness ... the industry, attended by many people already earning seven-figure incomes. ... is usually only open to the owners of Keuilian’s ... , This year’s Fit Body Boot Camp World Conference will ... a fitness boot camp or are struggling with ...
(Date:8/21/2014)... Minn. (PRWEB) August 21, 2014 ... social wellness solutions, announced today that it has entered ... medical best practices, mobile technology and predictive analytics for ... communities. , According to Michael Emerson , ... applied for two patents on the technology used in ...
Breaking Medicine News(10 mins):Health News:Modern Healthcare Names Aspen Advisors Among the Top 100 Employers in the Healthcare Industry for a Fourth Consecutive Year 2Health News:Learning to play the piano? Sleep on it! 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Hunhu Healthcare Enters into Licensing Agreement with Mayo Clinic 2
... Cancers and Colorectal Screening Among Key ProvisionsBETHESDA, Md., ... and its more than 10,000 physician members congratulate ... today for the introduction of "21st Century Cancer ... Treatment) Act" and their vow to renew the ...
... The ,Help is Here Express, bus tour will be ... 3 at various cities throughout the state in order ... programs that provide prescription medicines for free or nearly ... exceeding that of the nation (8.1 percent), the Partnership ...
... 26 BioMosaics Inc., a cancer biomarker ... antibody product (clone 1G12) for detection of ... as an immunohistochemical test for diagnosis of ... Laboratories is a state-of-the-art reference pathology laboratory ...
... average sodium intake far exceeds recommendations, raising health risks, ... American consumes far more salt each day than is ... from the U.S. Centers for Disease Control and Prevention ... high blood pressure, blacks, and middle-age and older adults ...
... new study by researchers at the University of British Columbia ... The study, published in the Journal of Public Health ... three times more likely than those who don,t to meet ... of physical activity. , Doctoral student Ugo Lachapelle and Assoc. ...
... Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: ... completed its acquisition of Genentech pursuant to a short-form ... the Roche Group. Roche had announced earlier in the ... expired on Wednesday, March 25. In connection with the ...
Cached Medicine News:Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 3Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 2Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 3Health News:Using Too Much Salt Is Common in U.S., CDC Says 2Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:Roche Completes Acquisition of Genentech 2
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Medicine Products: